A Repeatability Study of Fatty Acid Uptake Using PET/MR Imaging in Patients With T2DM and Non-diabetic Control Subjects

Diabetes Mellitus, Type 2 Clinical Trial

— AM05  

Official title:

Assessment of Fatty Acid Uptake and Blood Flow in Tissues Under Fasting and Postprandial Conditions; a Repeatability Study Using Dynamic PET/MR Imaging in Patients With Type 2 Diabetes and Non-diabetic Control Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05132335
• Other study ID #: AM05
• Status: Completed
• Phase: N/A
• Start date: March 29, 2021
• Est. completion date: April 30, 2022

Study information

• Verified date: August 2023
• Source: Turku University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the overall variation in the assessment of fatty acid uptake and blood flow in adipose tissue and skeletal muscle in the fasted and postprandial states by evaluating the repeatability of whole-body three-dimensional kinetic (4D) combined positron emission tomography and magnetic resonance imaging (PET/MRI) readouts in participants with type 2 diabetes mellitus (T2DM), and non-diabetic control participants. Each volunteer participates 4 scanning sessions.

Description:

A total of approximately 13 T2DM and 6 control subjects (a total of 19 subjects) are planned to be enrolled to achieve 11 T2DM and 5 control subjects to complete the study, assuming a 15% drop-out rate. The test-retest repeatability of the ratio of FTHA uptake rates in subcutaneous adipose tissue (SAT) to skeletal muscle is measured using the intra-class correlation coefficient (ICC). Assuming an ICC of 0.85, with a 5% two-sided type I error rate, a sample size of 16 completers will yield approximately 90% power to detect an ICC statistically significantly greater than 0.4 (usually considered as a criterion for moderate agreement). The total radiaooin burden for tshi sitdu yis 27.4 mSv. The study is approved by the local Ethical committtee and Fimea.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: April 30, 2022
• Est. primary completion date: November 25, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

• Have a body mass index (BMI) between 25 to 40 kilograms per meter squared (kg/m²),
• For participants with a confirmed type 2 diabetes diagnosis: The condition must be managed either by diet and exercise alone or on a stable dose of metformin
• For nondiabetic subjects: participants must agree to keep their diet and physical activity habits stable throughout the study
• Female participants must be post-menopausal and male participants

Exclusion Criteria:

• Poorly controlled diabetes
• Unstable body weight within 30 days prior to screening.
• For non-diabetic control subjects: evidence of diabetes or prediabetes at screening.
• Having worked as a metal worker or welder
• History of alcohol or drug abuse within 5 years of the screening
• Currently participating, or previous participation in another clinical trial within 30 days prior to the screening visit, or previous participation in another PET imaging study within 12 months.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2

Intervention

Other:
• Imaging Biomarkers
One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA([18F]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water([15O]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements. Assigned interventions: [18F]-FTHA tracer injections [15O]-H2O tracer injections PET/MRI imaging Overnight fasting Liquid meal ingestion

Locations

Country	Name	City	State
Finland	Turku PET Centre	Turku
Finland	Turku PET Centre (Turku University Hospital)	Turku

Sponsors (2)

Lead Sponsor	Collaborator
Turku University Hospital	Antaros Medical

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the repeatability of the ratio of subcutaneous adipose tissue (SAT) to skeletal muscle fatty acid uptake rates	The ratio of SAT to skeletal muscle fatty acid uptake rates	Baseline through Day 14